Interpace Biosciences Probability of Future OTC Stock Price Finishing Under 2.70
| IDXGDelisted Stock | USD 2.20 0.00 0.00% |
Interpace |
Interpace Biosciences Target Price Odds to finish below 2.70
The tendency of Interpace OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 2.70 after 90 days |
| 2.20 | 90 days | 2.70 | under 95 |
Based on a normal probability distribution, the odds of Interpace Biosciences to stay under $ 2.70 after 90 days from now is under 95 (This Interpace Biosciences probability density function shows the probability of Interpace OTC Stock to fall within a particular range of prices over 90 days) . Probability of Interpace Biosciences price to stay between its current price of $ 2.20 and $ 2.70 at the end of the 90-day period is about 14.15 .
Given the investment horizon of 90 days Interpace Biosciences has a beta of -1.22. This usually indicates as returns on its benchmark rise, returns on holding Interpace Biosciences are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Interpace Biosciences is expected to outperform its benchmark. In addition to that Interpace Biosciences has an alpha of 2.874, implying that it can generate a 2.87 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Interpace Biosciences Price Density |
| Price |
Predictive Modules for Interpace Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Interpace Biosciences. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Interpace Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Interpace Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Interpace Biosciences is not an exception. The market had few large corrections towards the Interpace Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Interpace Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Interpace Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.87 | |
β | Beta against Dow Jones | -1.22 | |
σ | Overall volatility | 0.69 | |
Ir | Information ratio | 0.12 |
Interpace Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Interpace Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Interpace Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Interpace Biosciences is not yet fully synchronised with the market data | |
| Interpace Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
Interpace Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Interpace OTC Stock often depends not only on the future outlook of the current and potential Interpace Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Interpace Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.2 M |
Interpace Biosciences Technical Analysis
Interpace Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Interpace OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Interpace Biosciences. In general, you should focus on analyzing Interpace OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Interpace Biosciences Predictive Forecast Models
Interpace Biosciences' time-series forecasting models is one of many Interpace Biosciences' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Interpace Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Interpace Biosciences
Checking the ongoing alerts about Interpace Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Interpace Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Interpace Biosciences is not yet fully synchronised with the market data | |
| Interpace Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |